期刊文献+

乳腺癌HLA-DR表达及其临床价值 被引量:2

Clinical significance of HLA DR antigen expression in breast cancer
暂未订购
导出
摘要 采用免疫组化技术,分析了40例乳腺癌石蜡标本主要组织相容性抗原HLA-DR与各项临床病理参数和生存预后的关系。根据HLA-DR阳性细胞的多少,40例病人分成两组:高阳性组(GH,>30%)和低阳性组(GL,≤30%)。结果显示:①HLA-DR表达与原发灶大小、淋巴结转移数、TNM分期、组织学分级无关,但与癌周淋巴细胞浸润显著相关(P<0.05);②高阳性组各时点生存率及总体生存率均显著高于低阳性组(P<0.05)。资料提示。 We studied 40 cases of breast cancer to examine the correlation of HLA DR antigen expression on tumor tissues with clinicopathological features.Immunohistochemistry was preformed by using a monoclonal antibody specifically against HLA DR.All tumor tissues were divided into two groups,depending on the rate of HLA DR positive cells(greater and lesser than 30%).The result showed that HLA DR expression was not associated with such clinicopathological parameters as tumor size,axillary lymth node metastasis,clinical TNM stage and histologic grade,but it was associated with peripheral lymphocyte infiltration.The group with high HLA DR expression(GH) demonstrated significantly better survival in comparison with the group with low expression(GL).We speculate that HLA DR expression in breast cancer cells exerts a favorable influence on clinical course.
出处 《实用肿瘤杂志》 CAS 北大核心 1998年第4期208-211,共4页 Journal of Practical Oncology
关键词 乳腺癌 病理学 HLA-DR 免疫组织化学 breast neoplasm/pathology histocompatibility antigen HLA DR/immunology prognosis
  • 相关文献

参考文献1

  • 1Chen P,J Leukocyte Biol,1994年,56卷,469页

同被引文献17

  • 1[1]Mota FF, Rayment NB, Kanan JH, et al. Differential regulation of HLA-DR expression by keratinocytes and langerhanss cells in normal and premalignant cervical epithelium[J]. Tissue Antigens, 1998, 52 (3): 286-293.
  • 2[2]Cabrera T, Ruiz-Caello F, Garrido F. Biological implications of HLA-DR expression in tumours[J]. Scand J Immunol, 1995, 41: 398-406.
  • 3[3]Menge AC, Mestecky J. Surface expression of secretory component and HLA class Ⅱ DR antigen on glandular epithelial cells from human endometrium and two endometrial adenocarcinoma cell lines [J]. J Clin Immunol,1993, 13(4): 259-264.
  • 4[6]Reinisch W, Holub M, Katz A, et al. Prospective pilot study of recombinant granulocyte-macrophage colonystimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma [J]. J Immunother,2002, 25(6): 489-499.
  • 5[7]Wetzler M, McElwain BK, Stewart CC, et al. HLA-DR antigen-negative acute myeloid leukemia [J]. Leukemia,2003, 17(4): 707-715.
  • 6[9]Lazaris AC, Theodoropoulos GE, Aroni K, et al. Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma[J]. Virchows Arch, 1995, 426 (5): 461-467.
  • 7Tamura M, Nishizaka S, Maeda Y, et al. Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes[J]. Jpn J Cancer Res,2001 Jul; 92(7):762~7.
  • 8Zambon A, Mandruzzato S, Parenti A, et al. MAGE, BAGE and GAGE geue expression in patients with esophageal aquamous cell carcinoma and adenocarcinoma of the gastic cardia[J]. Cancer,2001 May 15; 91(10): 1882~8.
  • 9Lanier LL, Corliss BC, WUJ Leong, et al.[J].cell, 1998,92: 705.
  • 10Yamaguchi Y, Ohta K, Shimizu K, et al. Generation of cyto toxic effector lymphocytes by MLTC using tumor cells genetically modified to secrete interleukin-2 [ J ]. Anticancer Res,2001 Jan-Feb; 21(1B): 669~77.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部